Investigating Achromobacter bacteria in cystic fibrosis patients on Réunion Island
Pathogenicity of Species of the Achromobacter Genus in Patients With Cystic Fibrosis: a Prospective Multicentre Exploratory Study of a Cohort in Réunion Island.
This study is trying to see how different types of Achromobacter bacteria affect lung health in cystic fibrosis patients living on Réunion Island.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 35 (estimated) |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de la Réunion Academic / other |
| Locations | 2 sites (Saint-Denis and 1 other locations) |
| Trial ID | NCT06371261 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the pathogenicity of Achromobacter species in cystic fibrosis patients residing on Réunion Island. By utilizing MALDI-TOF mass spectrometry for rapid identification of these bacteria, the study will assess the frequency of pulmonary exacerbations associated with different Achromobacter species. The research will focus on understanding the virulence and resistance of these bacteria, which could inform better management strategies for cystic fibrosis patients. The findings may lead to improved guidelines for dealing with Achromobacter colonization in clinical settings.
Who should consider this trial
Good fit: Ideal candidates include cystic fibrosis patients living in La Réunion Island who have tested positive for Achromobacter spp.
Not a fit: Patients without cystic fibrosis or those with cystic fibrosis but no Achromobacter-positive tests during the study period may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the management of cystic fibrosis by providing insights into the pathogenicity of Achromobacter species.
How similar studies have performed: While the pathogenicity of Achromobacter in cystic fibrosis is emerging, this specific approach using MALDI-TOF mass spectrometry for identification is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Minor or major cystic fibrosis patients * Patients with at least one sputum cytobacteriological test positive for Achromobacter spp. during the inclusion period. * Patients living in La Réunion island. * Patients for whom a non-opposition was obtained orally (if applicable from both one of the child's legal guardians and the child him/herself) Exclusion Criteria: * Patients without cystic fibrosis. * Patients with cystic fibrosis but no Achromobacter-positive ECBC during the study inclusion period
Where this trial is running
Saint-Denis and 1 other locations
- CHU la Réunion North — Saint-Denis, Réunion (Recruiting)
- CHU la Réunion South — Saint-Pierre, Réunion (Recruiting)
Study contacts
- Study coordinator: Thomas GARRIGOS, Pharm D, PhD
- Email: thomas.garrigos@chu-reunion.fr
- Phone: +262 (0)2 62 90 62 67
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.